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Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of antidepressant 
medications that came on the market in the late eighties and early nineties. SSRIs were 
found to be clinically effective in treating clinical depression, and anxiety disorders in 
adults and had less cumbersome side effects compared to the older Tricyclic 
antidepressants.1 The first drug in this class introduced was fluoxetine (Prozac), which 
was soon followed by paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), 
fluvoxamine (Luvox), and escitalopram (Lexapro).  Today the uses of SSRIs have 
broadened to include treatment for “Post-Traumatic Stress Disorder, pre-menstrual 
dysphoric disorder, urinary incontinence” and many other seemingly unrelated 
conditions.2 In North America, “it is estimated that 2% of children and up to 8% of 
adolescents suffer from a depressive disorder.  In addition, at least 10% of youth suffer 
from anxiety disorders.”3 Given the prevalence of childhood depression and anxiety 
disorders, it is not surprising that in the 1990’s and early 2000’s, SSRIs became the 
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* Kim Wilton is a second-year law student at Dalhousie University’s Schulich School of Law. She 
is currently articling with Ottenheimer Baker in St. John’s, Newfoundland. 
 
1 Rebecca Ronsley et al, “Do Hospital and Community SSRI Usage Patterns in Children and 
Adolescents Match the Evidence?” (2010) 19:3 Journal of the Canadian Academy of Child and 
Adolescent Psychiatry 218.  
2 Trudo Lemmens & Ron A Bouchard, “Regulation of Pharmaceuticals in Canada” in Jocelyn 
Downie, Timothy Caulfield & Colleen M Flood eds, Canadian Health Law and Policy (Markham: 
LexisNexis, 2007) at 335.  
3 Ronsley, supra note 1 at 218.  
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treatment of choice in fighting childhood depression and anxiety.4  Not only were SSRIs 
prescribed to adolescents and prepubescent children, they were commonly prescribed to 
kindergarten aged children and even infants less than a year old.5  
 
However, SSRIs were not clinically tested for use in children and adolescents, nor were 
they approved for use in children and adolescents.  SSRIs were prescribed to children 
and adolescents “off-label” by physicians, meaning SSRIs had not received approval for 
use in these age groups by Health Canada. In the first part of the 21st century, concerns 
began to arise concerning the use of these drugs in children and adolescents as reports 
began to emerge demonstrating that in many cases SSRIs were associated with an 
increase in suicidal behavior and thoughts in children and adolescents.6  Despite being 
subjected to regulatory warnings from Health Canada and intense media coverage, 
SSRIs are still widely prescribed to children and adolescents.  
 
In this paper, I will review how SSRIs are currently regulated for use as a treatment for 
depression and anxiety in children and adolescents in Canada by examining the roles of 
the different actors involved, including: drug manufacturers, regulatory bodies, 
professional associations, physicians, parents and the patients themselves. In Part II of 
this paper I will discuss the 2004 warnings issued by regulatory agencies in Canada, the 
USA and the UK, against the use of SSRIs in children and adolescents; in Part III I will 
analyze the current off-label status of SSRIs for children and adolescents and the current 
system used by physicians to prescribe SSRIs to children and adolescents; and in Part IV 
I will discuss the problems that exist with the current system by examining the roles of 
each of the abovementioned actors. Finally, in Part V, I will make suggestions as to how 
the current system can be reformed and improved. The continued off-label use of SSRIs 
in children is not only dangerous for short-term use in children and adolescents, but 
could also have dangerous long-term effects as the consequences of SSRIs on child and 
adolescent development is unknown. The current regulatory system fails to protect this 
vulnerable population and exposes them to unwarranted and unnecessary risks. A new 
system is needed in which drug manufacturers are more accountable, regulatory 
warnings are more forceful, the ability of physicians to prescribe off-label is curtailed, 
and patients and their parents are more informed about treatment options.  
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4 The prescribing of a wide variety of psychotropic medication: Tricyclic Antidepressants, 
neuroleptic prescriptions, and ADHD medications, to children and adolescents has been increasing 
“dramatically” in the USA and Canada for the past several decades: see Audrey L. Zakriski, et al. 
“Justifiable Psychopharmacology or Overzealous prescription? Examining Parental Reports of 
Lifetime Pre-Prescription Histories of Psychiatrically Hospitalized Children” (2005) 10:1 Child 
and Adolescent Mental Health; Sharon Kirkey, “Psychiatry’s Bible: Book could roll out a whole 
new list of disorders and more prescriptions for psychoactive drugs” Canwest News Service (26 
April 2010); Many physicians have criticized what they see as an “overzealous prescribing” of 
psychotropic medications in children and adolescents: Raymond Behr, “Overzealous Prescribing 
of Medications” (1998) 37:9 Journal of the American Academy of Child and Adolescent 
Psychiatry 900. 
5 Jonathan Leo, “The SSRI Trials in Children: Disturbing Implications for Academic Medicine” 
(2006) 8:1 Ethical Human Psychology and Psychiatry 29 at 30.  
6  Ibid. 




I. THE 2004 WARNINGS: THE DARK SIDE OF SSRIs 
 
Between 2003 and 2004, concerns arose about the safety and effectivity of SSRI use in 
children. Reports and meta-analyses of randomized controlled trials (RCTS) showed that 
SSRI use in children was correlated with increased risks of suicidal behavior and 
thoughts (also known as suicidality).7 Notably, the SSRI Paxil was found to create two 
times as much suicidal idolization in childhood, compared to a placebo.8 The use of 
SSRIs was also linked to suicides in adults;9 however, studies have demonstrated that the 
link between SSRIs and increased sucidiality in adults is small or non-significant.10  
There were also reports that some drug manufacturers had misled the public and health 
regulatory agencies about the safety of these drugs in children and adolescents. In one 
instance, a leaked internal document from management at GlaxoSmithKline, the 
manufacturers of Paxil, “advised staff to withhold clinical trial findings in 1998 that 
indicated the antidepressant paroxetine (Paxil) had no beneficial effect in treating 
adolescents.”11  
 
In the USA, then attorney general of New York, Eliot Spizter, launched a lawsuit against 
GlaxoSmithKline stating the company “committed fraud by withholding negative 
information and misrepresenting data on prescribing its antidepressant Paxil to 
children.”12 Not only was it alleged that GlaxoSmithKline hid clinical trials but also that 
the company used “a highly selective set of data to promote off-label prescription of the 
drug to treat children and adolescents.”13 This lawsuit illustrated the striking lack of 
regulation surrounding SSRI use in children and adolescents and “raised troubling 
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7 Benedict W. Wheeler et al, “International impacts of regulatory action to limit antidepressant 
prescribing on rates of suicide in young people” (2009) 18:7 Pharmacoepidemiology and Drug 
Safety 579 at 579.  
8 Interview of Dr. Aidan Stokes, Deputy Head of the Dalhousie Department of Psychiatry (12 
November 2010) Halifax, Nova Scotia.  
9 Anonymous, The Lancet (14 June 2005) online: The Lancet <http://thelancet.com>. 
10 Peter Roy-Byrne, “SSRIs and Suicide Risk: A Concern for Adults, Too?” Journal Watch 
Psychiatry (9 March 2005) online: Journal Watch <http://www.jwatch.org>; Amy Cheung, 
“Review: SSRIs are associated with increased risk for attempted or completed suicide in 
adolescents but not in adults or the elderly,”  (2009) 150:2 Annals of Internal Medicine JC6-13; 
Carrado Barbui, Eleonora Esposito and Andrea Cirpriani, “Selective Serotonin Reuptake inhibitors 
and risk of suicide: a systematic review of observational studies” (2009) 180:3 Canadian Medical 
Association Journal. Robert Gibbons and J John Mann, “Proper studies of selective serotonin 
reuptake inhibitors are needed for youth with depression, (2009) 180:3 Canadian Medical 
Association Journal. According to Gibbons and Mann: the FDA extended “the “black box” 
warning for use of antidepressants” for ages 18-25. The June 2004 Health Canada Warning against 
SSRI use was directed to patients of all ages, not just patients under the age of 18. 
11 Wayne Kondro, “Drug company experts advised staff to withhold data about SSRI use in 
children” (2004) 170:5 Canadian Medical Association Journal.  
12 “Spitzer sues GlaxoSmithKline over Paxil,” Associated Press (2 June 2004) online: MSNBC 
<http://www.msnbc.msn.com >; AG New York v GlaxoSmithKline, this case was eventually settled 
out of court; Trudo Lemmens, “Leopards in the Temple: Restoring Scientific Integrity to the 
Commercialized Research Scene” (2004) 32 L Med Ethics 641.  
13 Lemmens & Bouchard, supra note 2 at 335. 
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questions about the ability of pharmaceutical companies to control and manipulate 
medical research.”14 Academic journals such as The British Medical Journal (BMJ), 
conducted reviews of clinical trials of SSRI use in children and adolescents and 
concluded these trials “had exaggerated the benefits and downplayed the risks.”15 A 
review published in The Lancet demonstrated that when SSRIs are used in children and 
adolescents, “the benefits do not outweigh the risks” and that there seemed “to be a 
systematic bias toward downplaying the suicide issue.”16 Further studies revealed that 
not only did SSRI use in children and adolescents result in an increased risk of 
suicidality, but also that the benefits of SSRIs were very small when compared to a 
placebo.17  
 
These reports received a lot of media attention and led to regulatory warnings in many 
countries. In the USA, consumers launched multiple lawsuits against drug 
manufacturers, and the Food and Drug Administration (FDA) issued a “black box” 
warning on SSRI use for children and adolescents—meaning a warning that “appears on 
a prescription drug’s label and is designed to call attention to serious or life-threatening 
risks.”18 This warning cautioned physicians and patients that “antidepressants increase 
the risk of suicidal thinking and behavior (suicidality) in children and adolescents with 
major depressive disorder and other psychiatric disorders.”19 In the UK, the Committee 
on the Safety of Medicine also released a warning against the use of Paxil in children 
and adolescents. However, shortly afterwards, the UK Medicine and Healthcare Products 
Regulatory Agency surmised that all SSRIs, with the exception of fluoxetine (Prozac), 
should not be used in children and adolescents.20 
 
In Canada, Health Canada issued a warning on February 3, 2004 against the use of 
SSRIs in children and adolescents. This warning stated that people under the age of 18 
“should consult their treating physician to confirm that the benefits of the drug still 
outweigh its potential risks in light of recent safety concerns.”21 These “safety concerns” 
arose from reports that “some of these drugs may be associated with an increased risk of 
suicide-related events in patients under 18 years of age.”22  Health Canada released a 
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14 Ibid at 336.  
15 Leo, supra note 5 at 36.  
16 Ibid at 37.  
17 Ibid. 
18 FDA, Fact Sheet, “A Guide to Drug Safety Terms” online: US Food and Drug Administration 
,http://www.fda.gov>; Jonathan Mahler, “The Anti-Depressant Dilemma” The New York Times 
Magazine (21 November 2004), online: The New York Times <http://www.nytimes.com>; 
Dickman, Hagar. "In the courts: pharma-immunity from paxil-related adolescent suicide suits" 
(2008) 28:2 Child Legal Rts J 57. 
19 Elizabeth Weller, Sheridan Tucker & Ronald Weller “The Selective Serotonin Reuptake 
Inhibitors and the Treatment of Depression in children” (2005) 7:2 Current Psychiatry Reports 
2005 87 at 88. 
20 Stan Kutcher & David M Gardner, “Use of selective serotonin reuptake inhibitors and youth 
suicide: making sense from a confusing story” (2008) 21 Current Opinion in Psychiatry 65 at 66. 
21 Health Canada, Advisory, “Health Canada Advises Canadians Under the Age of 18 to Consult 
Physicians if they are Being Treated with Newer Anti-Depressants”, (Ottawa: Health Canada, 3 
February 2004) online: Heath Canada <http://ww.hc-sc.gc.ca>. 
22  Ibid.  
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second warning in June 2004: 
 
advising Canadians that SSRIs and other newer anti-depressants now carry 
stronger warnings. These warnings indicate that patients of all ages taking 
these drugs may experience behavior and/or emotional changes that may put 
them at increased risk of self-harm or harm to others.23  
 
 
II. THE CURRENT SYSTEM 
 
Off-Label Prescriptions  
Currently, Health Canada does not approve the use of SSRIs for children and 
adolescents; therefore, any SSRI prescribed to children in Canada is prescribed off-label. 
Physicians very often prescribe off-label drugs for children and adolescents. Since most 
medicines have only been approved for use in adults, a child suffering from the same 
condition will often be prescribed the same medication. It has been recognized that "off-
label use may represent the only, or best, treatment available for a specific illness in a 
child."24  Some argue that the term “off-label” would be more accurately described as 
“silent label” since “the term denotes nothing about health risks or benefits.”25  
While there are not any SSRIs approved for use in children in Canada, the same is not 
true in the USA. Shortly after issuing the “black box” warnings on SSRIs for use in 
children, the Food and Drug Administration approved the use of fluoxetine for the 
treatment of depression for children between the ages of 12 and 17.26 More recently, the 
FDA has approved escitalopram for the treatment of depression in adolescents between 
twelve and seventeen years of age.27 Indeed, subsequent studies showed that while “the 
therapeutic effect of SSRI treatment in young people below puberty may be 
insignificant,” there is “reasonable evidence to support use of SSRIs as a treatment for 
adolescent depression and other disorders.”28  
When prescribing off-label, doctors take into account factors like their own experience, 
the experiences of their colleagues, and academic literature.29 If a drug is being used for 
a condition in adults, then doctors tend to use that drug for children and adolescents with 
the same condition. There are disorders, such as Obsessive Compulsive Disorder, that 
present the same way in both children and adults, but some disorders manifest differently 
in children and adults; therefore, one cannot extrapolate the use of the same drug used in 
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23 Health Canada, Advisory, “Health Canada Advises Canadians of Stronger Warnings for SSRIs 
and other Newer Anti-Depressants”, (Ottawa: Health Canada, 3 June 2004) online: Heath Canada 
<http://ww.hc-sc.gc.ca>. 
24 Natalie de Paulsen, “The Regulatory Gap: Off-Label Drug Use in Canada” (2005) 63 UT Fac L 
Rev 183 at para 4.  
25 WA Meadows & BD Hollowell, “‘Off-label’ drug use: an FDA regulatory term, not a negative 
implication of its medical use” (2008) 20 International Journal of Impotence Research 135 at 140. 
26 Ronsley, supra note 1 at 219.  
27 Ibid.  
28 Kutcher & Gardner, supra note 20 at 68. 
29 Stokes, supra note 8.  
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adults for use in children without taking these factors into account.30 
 
Another factor that can influence Canadian doctors when prescribing off-label is the 
USA’s Food and Drug Administration approval or other international regulatory 
approval. While the FDA does not influence Health Canada, FDA approval of a drug can 
and does influence individual doctors when prescribing medications.31 
 
Finally, the existence of professionally recognized prescribing guidelines also influences 
the prescribing of medications for off-label uses. For example, the Canadian Psychiatric 
Association (CPA) (the national professional organization of psychiatrists in Canada) 
published guidelines in the wake of the 2004 Health Canada warnings. These guidelines 
describe when and how SSRIs should be prescribed to treat depression and anxiety in 
children and adolescents.  According to these guidelines, “only fluoxetine is considered a 
first line treatment for depression in children and adolescents”; any other SSRIs: 
 
can be considered as second-line treatments, especially when the depression 
is severe, chronic, associated with comorbid conditions, and/or when 
psychosocial treatments such as CBT [Cognitive Behaviour Therapy] have 
not worked.32  
 
Further, the CPA guidelines state that the appropriate standard of care in prescribing 
SSRIs to children involves weekly appointments or telephone contacts for the first 
month to monitor for adverse effects including suicidality. 
 
The Canadian Academy of Child and Adolescent Psychiatry (CACAP) is the national 
organization of child and adolescent psychiatrists. It has also published guidelines for the 
use of SSRIs in children and adolescents. The CACAP “strongly suggest that medication 
should not be prescribed outside of a comprehensive treatment approach that includes” 
psychotherapy and psycho-education. However, CACAP acknowledges that “fluoxetine 
may be the medication of choice for use in both MDD [Major Depressive Disorder] and 
anxiety disorders.” 33  Further, the CACAP cautions that “such as venlafaxine and 







30 Ibid.  
31 Interview of Dr. David Gardner, Professor with the Dalhousie Department of Psychiatry and 
College of Pharmacy (12 November 2010) Halifax, Nova Scotia.  
32 Raymond W Lam & Sidney H Kennedy, “Prescribing Antidepressants for Depressant in 2005: 
Recent Concerns and Recommendations” The Canadian Psychiatric Association (8 October 2004) 
online: The Canadian Psychiatric Association <http://www.cpa-apc.org>. 
33 E. Jane Garland, Stan Kutcher & Adil Virani, “2008 Position Paper on Using SSRIs in Children 
and Adolescents” (2009) 18:2 Journal of the Canadian Academy of Child and Adolescent 
Psychiatry 160 at 164.  
34  Ibid.  
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III. HOW THE CURRENT SYSTEM FAILS CHILDREN AND ADOLESCENTS 
 
Drug Manufacturers  
 
i) Clinical Testing and Drug Approval  
 
Once a drug is approved by Health Canada for adult use, drug manufacturers have to 
apply to have the same drug approved for use in a new population or for a new 
condition. Thus, as SSRIs are approved for use in adults, manufacturers of SSRIs would 
have to reapply to Health Canada to get the same medications approved for use in 
children and adolescents. Drug companies are risk adverse and applying to have a drug 
approved for another population is an additional expense for them.35 Conducting drug 
trials with children and adolescents is more complex and complicated than drug trials 
with adults. Since diseases such as depression and anxiety do not start at age eighteen, it 
is easy for drug companies to assume that their drugs will be used for the same condition 
in children as in adults even without regulatory approval.36 Indeed, there is a general 
reluctance on the part of drug companies to conduct clinical drug testing in children.37 In 
contrast to clinical trials with adults, factors such as parental consent play an important 
role in clinical trials with children and adolescents. Moreover, “it is difficult to recruit 
children for clinical trials.”38 This helps explain why before “1997, no published reports 
demonstrating superior efficacy of SSRIs over placebo in children and adolescents 
existed.”39  
 
When a drug is prescribed off-label, it means it has not been subjected to the same 
rigorous standard of testing and review as approved drugs. For a new drug to be 
approved by Health Canada, it must go through four stages: “Preclinical Studies, Clinical 
Trials, New Drug Submission and Marketing.”40 All these stages must be based on 
Canadian studies and supportive evidence has to come from Canadian experiences.  The 
Food and Drugs Regulations (FDR) divide clinical trials into four different categories, 
which vary in “size and purpose.”41 Phases I-III are the clinical trials which determine 
whether a drug is approved or not, while Phase IV trials occur after a drug has been 
approved.42 It is during Phase IV trials that the “long-term efficacy and safety of the 
drug” are assessed.43 However, since SSRIs have not been approved for use in children, 
these medications have not been subjected to Phase IV trials with children and 
adolescents, and the long-term efficacy of these medications remains unknown. This is 
particularly troubling since the long-term effects of SSRIs on a child’s emotional, 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
35 Gardner, supra note 31.  
36 Ibid. 
37 Ibid.  
38 de Paulsen, supra note 24 at para 4.  
39 Ronsley, supra note 1 at 218.  
40 Lemmens & Bouchard, supra note 2 at 321.  
41 Ibid at 322. 
42 Ibid at 323 & 322.  
43 Ibid at 322. 
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physical and “sexual development” remains unknown.44 It is not just the lack of long-
term effects of these medications that remain unknown, but many short-term effects as 
well. 
 
Under the FDR, all clinical trials must follow strict guidelines. For one, clinical trials 
must be approved by a research ethics board (meaning “a body that is not affiliated with 
the sponsor”45) before a clinical trial begins.46 Further, all clinical trials must follow 
good clinical practices as set down in section C.05.010 of the FDR.  A drug 
manufacturer is required to keep “complete and accurate records” of a clinical trial, 
including: 
 
records respecting all adverse events in respect of the drug that have 
occurred inside or outside Canada, including information that specifies 
the indication for use and the dosage form of the drug at the time of the 
adverse event.47 
  
Research ethics in Canada are also informed by the Tri-Council Policy Statement: 
Ethical Conduct for Research Involving Humans (TCPS) of The Interagency Advisory 
Panel on Research Ethics (PRE). 48  The TCPS conveys the PRE’s “continuing 
commitment to the people of Canada to promote the ethical conduct of research 
involving humans,”49 and sets duties upon researchers attempting to conduct research on 
humans. Article 1.1 states the guiding principles of the TCPS: “respect for persons, 
concern for welfare and justice.”50 The TCPS places a duty on researchers of clinical 
trials to ensure: 
 
(a) foreseeable risks to participants are minimized, and appropriately 
evaluated alongside potential benefits, (b) participants are clearly 
informed as to the nature of these foreseeable risks and potential 
benefits, (c) participant safety is monitored and accurately reported, and 
(d) any new information that may impact on the welfare of participants, 
or their decision to remain involved in a trial, be shared appropriately.51 
 
The TCPS places similar duties on researchers with regards to consent. According to the 
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44 Nicola Glover-Thomas, “Off-Label Paediatric Drug Use for Juvenile Depression and the 
Clinical Drug Regulations 2004: The Impact of Available Protective Mechanism” (2008) 29 
Liverpool Law Review 205 at 207.  
45 Food and Drugs Regulations, CRC c 870 C. 05.001 [FDR]. 
46 Ibid, C.05.010(d). 
47 Ibid, C.05.012(3)(c).  
48 Panel on Research Ethics, Fact Sheet, “About us” online: Panel on Research Ethics 
<http://www.pre.ethics.gc.ca>. 
49 Panel on Research Ethics, Tri-Council Policy Statement: Ethical Conduct for Research 
Involving Humans, “Introduction,” online: Panel on Research Ethics 
<http://www.pre.ethics.gc.ca>. 
50 Panel on Research Ethics, Tri-Council Policy Statement: Ethical Conduct for Research 
Involving Humans, “Chapter 1,” online: Panel on Research Ethics <http://www.pre.ethics.gc.ca>. 
51Ibid, Chapter 11. 
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TCPS, for children to participate in clinical trials, researchers must obtain consent from 
“authorized third parties in accordance with the best interests of the persons 
concerned.”52  
 
Currently, most of the clinical trials of SSRI use in children and adolescents are smaller 
trials sponsored by drug manufacturers.53 Although some of these trials may provide as 
rigorous and thorough of an assessment as ones conducted under the FDR requirements, 
there is great potential for the results of these trials to be biased or skewed when 
compared to those conducted for Health Canada approval. This is very troubling since, 
as demonstrated in Part II of this paper, manufacturers of SSRIs have in the past misled 
the public and regulators about data from their clinical trials.  
 
ii) Manufacturer Liability and the Learned Intermediary 
 
In the USA, most of the lawsuits involving manufacturers of SSRIs and children concern 
severe side effects that arose from off-label use. Cases such as, Miller v Pfizer, are 
multifold in the USA. In Miller, the parents of a thirteen-year-old boy who killed himself 
while taking Prozac unsuccessfully sued the manufacturers of Prozac, Pfizer, alleging 
that Prozac made their son suicidal.54 In O’Neal v SmithKline Beechman Corporation, 
the plaintiff sued the makers of Paxil alleging the company should have warned the 
public about increased risks of suicidality in children and adolescents when taking Paxil. 
The plaintiff’s son was prescribed Paxil and attempted suicide, later dying from his 
injuries. The case was dismissed because the plaintiff’s son had died seven years before 
the Food and Drug Administration issued its black box warning and required 
manufacturers to include information about increases in suicidality on their packaging.55 
In Hoorman v SmithKline, the plaintiffs launched a class action suit against the makers 
of Paxil, alleging the company “used its marketing and sales force to encourage doctors 
to prescribe Paxil off-label to pediatric patients.” Hoorman settled outside of court with 
the plaintiff’s “out-of-pocket expenses related to their Paxil purchase” refunded and 
without the company admitting any wrongdoing. After the settlement, the defendants 
continued to maintain: “Paxil was prescribed off-label based solely on the discretion of 
doctors.”56  
 
By contrast, Canadian case law is sparse in this area and there have been no Canadian 
lawsuits involving patients or their parents suing manufacturers of SSRIs for adverse 
side effects they experienced. The leading Canadian case on the liability of 
manufacturers of medical products is Hollis v Dow Corning. In Hollis, the Supreme 
Court of Canada noted that there is often a power imbalance between patients and 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
52 Ibid, Chapter 3, article 3.9.  
53 Gardner, supra note 31.  
54 Miller v Pfizer, Inc, 356 F (3d) 1326 (10th Cir 2004); Jonathan Mahler, “The Anti-Depressant 
Dilemma” The New York Times Magazine (21 November 2004), online: The New York Times 
<http://www.nytimes.com>. 
55 O’Neal v SmithKline Beechman Corporation, 551 F Supp (2d) 993 (2008); Dickman, Hagar. "In 
the courts: pharma-immunity from paxil-related adolescent suicide suits" (2008) 28:2 Child Legal 
Rts J 57 at 58. 
56 Ibid. Hoormann, et al v GlaxoSmithKline Beecham Corp., 04-L-715 (Ill Cir Cr 2006).  
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manufacturers, or patients and physicians; therefore manufacturers have a duty to warn 
consumers of any dangers associated with their product.57 This duty creates “a heavy 
onus on manufacturers of medical products” due to the “intimate relationship between 
medical products and the consumer’s body.”58 Further, this duty: 
 
serves to correct the knowledge imbalance between manufacturers and 
consumers by alerting consumers to any dangers and allowing them to 
make informed decisions concerning the safe use of the product.59 
  
Although Hollis involved the manufacturer of breast implants, and not off-label uses of 
medication, it still provides a framework upon which future claims of liability against 
drug manufacturers for the experience of severe side-effects from the off-label use of 
their product may be based. 
 
A recent case decided by the Ontario Supreme Court, Goodridge v Pfizer Canada Inc., 60 
may perhaps provide the most illustrative example as to how Canadian courts might 
approach the issue of manufacturer liability for severe side effects caused by off-label 
drug prescriptions. In Goodridge, a group of plaintiffs attempted to launch a class action 
lawsuit against Pfizer, the maker of the drug Neurontin, as well as the manufacturers of 
the generic version of the drug. Neurontin is approved by Health Canada for the 
treatment of epilepsy. The plaintiffs were prescribed Neurontin off-label for treatment of 
pain and alleged they experienced suicidal behavior while taking the drug. The plaintiffs 
alleged Pfizer was negligent “to Neurontin consumers by falsely and wrongfully 
promoting Neurontin for ‘off-label’ uses” and by “designing and distributing a drug that 
was useless for its off-label uses.”61 The court noted the standard set down in Hollis is 
useful for assessing negligence by drug manufacturers concerning the duty to warn 
consumers of dangers associated with their product. 
 
 In Goodridge and Hollis, the courts noted a manufacturer’s duty to warn consumers can 
be dismissed if the manufacturer gives “an adequate warning to a ‘learned 
intermediary,’” such as a physician.62 When dealing with prescription drugs: 
 
the duty of manufacturers to warn consumers is discharged if the 
manufacturer provides prescribing physicians, rather than the consumers, 
with an adequate warning of the potential dangers associated with the 
use of the drug.63  
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57 Hollis v Dow Corning Corp., [1995] 4 SCR 634 at para 21, 129 DLR (4th) 609 [Hollis].  
58 Ibid at para 23. 
59 Ibid at para 21. 
60 Goodridge v Pfizer Canada Inc., 2010 ONSC 1095, [2010] OJ No 655 [Goodridge].In 
Goodridge, the plaintiffs made a motion seeking a certificate of class action against the 
Defendants, and the Defendants made a motion to strike out part of the Plaintiff’s statement of 
claim. The Plaintiffs were granted their certificate and the Defendants were successful in striking 
out portions of the Plaintiff’s statement of claim. 
61 Ibid at para. 5. 
62 Hollis, supra note 57 at para 85. 
63 Ibid. 




Underlying this rule, is that if a patient is primarily reliant on: 
 
the judgment of a learned intermediary and not the manufacturer of the 
product, then the manufacturer will satisfy its duty to warn the consumer 
by adequately warning the learned intermediary of the risks inherent in 
the use of the product.64  
 
Thus, in a lawsuit, the manufacturers of SSRIs could argue they discharged their duty to 
the patient by providing sufficient warnings about increases in suicidality or other severe 





i) Post-Approval Marketing and Off-Label Drugs 
 
Health Canada is the regulatory body responsible for food and drug products in Canada. 
The Therapeutic Products Directorate (TPD), through the Food and Drugs Act (FDA) 
and the FDR, assesses the safety and effectiveness of medications.65 Health Canada only 
regulates on-label drugs, i.e. drugs that they have approved for use. Thus, the use of 
SSRIs in children and adolescents is not specifically monitored by Health Canada since 
these drugs are prescribed off-label.  However, Health Canada does in a sense monitor 
off-label uses of a drug through post-approval monitoring to make sure drug companies 
comply with the FDA and the FDR.66  
One of the ways in which Health Canada monitors drugs after approval is through 
“post-market surveillance,” 67  which involves gathering “reported adverse 
reactions that occur after drug use.”68 The FDR defines adverse reactions as: “a 
noxious and unintended response to a drug, which occurs at doses normally used 
or tested for the diagnosis, treatment or prevention of a disease or the 
modification of an organic function.”69  
 
These adverse reactions are not confined to reactions arising from on-label uses, but also 
include adverse reactions from off-label uses as well. Section C.01.016 of the FDR 
stipulates that if during any clinical trials a drug manufacturer becomes aware of any 
drug reaction or any adverse drug reaction, the manufacturer must:  
 
(a) a report of all information in respect of any serious adverse drug 
reaction that has occurred in Canada with respect to the drug, within 15 
days after receiving the information; and (b) a report of all information 
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in respect of any serious unexpected adverse drug reaction that has 
occurred outside Canada with respect to the drug, within 15 days after 
receiving the information. 
 
Section C.01.017 of the FDR makes drug manufacturers legally required to “maintain 
records of the reports and case reports” of adverse reactions. Patients and healthcare 
professionals can also report adverse reactions, however, this is done on a voluntary 
basis. Patients can fill out the “Consumer Side Effect Reporting Form” describing their 
adverse reactions and physicians can fill out the “Canada Vigilance Adverse Reaction 
Reporting Form.”70 Given that physicians only report adverse effects on a voluntary 
basis, potentially, adverse effects not reported by drug manufacturers could remain 
undetected and comprise public safety.  
The Canadian Adverse Reaction Information System (CADRIS) collects this data and 
analyzes it to “discover potential health product safety signals.”71 The discovery of a 
signal is “considered to be the preliminary indication of a product-related issue.”72 
Before any regulatory action is taken against a drug, adverse reactions need to undergo a 
“preliminary evaluation” which considers:  
 
the frequency, severity, plausibility, quality of the information contained 
in the reports, amount of product used, time needed for appearance of 
the reaction, underlying diseases, simultaneous use of other medications, 
and evidence of disappearance or reappearance of the reaction once the 
product was discontinued or reintroduced.73  
 
Thus, a reaction that is considered to be very “severe” might not be subject to regulatory 
action if this reaction has occurred in only a small number of patients. Placing emphasis 
on the “severity” of a reaction can have serious consequences for children and 
adolescents, since less severe reactions could have potential long-term consequences on 
their development. If a strong “signal” is identified, Health Canada has a variety of 
regulatory responses available to it, such as: post-marketing studies; “dissemination of 
information to healthcare professionals and consumers (e.g. letters, advisories, 
publications, specialized internet sites)”; “product labeling changes (including addition 
of contraindications, warnings, precautions or supplementary AR information on the 
product information or Product Monograph)”;  “issuing of public alerts”; and 
“conducting market withdrawals.”74 Further, a medication’s monograph must include 
“any potential side effects.”75 One could argue that the 2004 Health Canada warnings 
against the use of SSRIs in children demonstrate that the current regulatory system 
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works efficiently and protects the public. Once the adverse reactions of increased 
suicidality were identified, Health Canada responded by issuing a public warning 
concerning the existence of these symptoms.  
 
ii) Health Canada Proposals for Reform 
 
The weaknesses in the current regulatory system regarding off-label uses of medication 
have not gone unnoticed by Health Canada. Blueprint for Renewal: Transforming 
Canada’s Approach to Regulating Health Products and Food was released by Health 
Canada in 2006 as a proposal on how to change the current regulatory system.76 The 
Blueprint proposes “placing a risk-benefit framework at the forefront of the regulatory 
approval process, replacing the current FDA and regulations with new legislation.”77 
Notably, the proposal “expresses a clear concern for patient safety” and attempts to 
address the inadequacy of the current regulatory system regarding post-approval 
monitoring of drugs. 78  Proposed improvements include: “‘probationary’ regulatory 
approval contingent on post-marketing surveillance of adverse effects,” “jurisdiction to 
require sponsors to conduct post-market studies” and “initiatives to address under 
reporting of post-marketing adverse effects.”79  
 
In 2008, many of the proposals of the Blueprint for Renewal were incorporated into Bill 
C-51- An Act to amend the Food and Drugs Act. The bill, however, has not yet been 
passed by parliament.80 Thus, the proposed changes to the regulatory process have not 
been adopted. If adopted, they would make welcome changes to the post-approval 
regulation of drugs and place more responsibility on drug manufacturers to continuously 
monitor their product to ensure that their drugs are safe for patients. Nevertheless, even 
if the Blueprint for Renewal were adopted in full, there would still be problems with off-
label drug use. The proposed changes appear to be directed at on-label uses, thus still 
leaving the issues of off-label prescribing unchanged and mainly unregulated.  
 
iii) Health Canada Does Not Regulate The “Practice of Medicine” 
 
One of the biggest problems with the current regulatory system is that the practices of 
medicine and pharmacy are the domain of the provinces, territories and the provincial 
Colleges of Physicians and Registrars of Pharmacy. 81  Health Canada  “has no 
jurisdiction over how health care professionals prescribe drugs once they are 
approved.” 82 Even the local regulatory bodies leave doctors with a great deal of 
discretion when prescribing medication. According to Health Canada: “a physician's 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
76 Ibid at 361.  
77 Ibid.  
78 Ibid. 
79 Ibid at 362.  
80 Canada, Bill C-51, An Act to amend the Food and Drugs Act and to make consequential 
amendments to other Acts,  2nd Sess, 39th Parl, 2008 (debates at second reading 10 June 2008).  
81 Canada, Health Products and Food Branch, Report, “Response to Recommendations to Health 
Canada of the Coroner’s Jury into the Death of Ashley Marie Atkinson” (29 July 2003), online: 
Health Canada <http://www.hc-sc.gc.ca>. 
82 Ibid. 
Vol 20 Dalhousie Journal of Legal Studies 
!
141 
decision to prescribe particular medication for an individual patient be it for an 
indication listed on an approved drug's labeling or otherwise, is part of the ‘practice of 
medicine.’”83 Thus, Health Canada has no regulatory authority over the ability of 
physicians to prescribe medications off-label. This is especially troubling for 
medications that Health Canada has issued a warning against. Although Health Canada 
has issued warnings about the use of SSRIs in children, these medications are still 
widely prescribed in children. Essentially, due to the great deal of discretion physicians 
possess to prescribe medications, Health Canada warnings lack strength and are rendered 





i) The Standard of Care 
 
Whether or not physicians should be held liable for prescribing SSRIs to children and 
adolescents should be assessed through medical negligence. For a negligence claim to 
succeed, a plaintiff has to show:  
  
(a) the defendant owed the plaintiff a legal duty of care; 
(b) the defendant breached that duty of care; 
(c) the plaintiff suffered legally recognized damage;  
and (d) the damage was caused by the defendant’s breach of the duty of care.84 
 
In medical negligence claims, the standard of care doctors owe their patients is usually 
assessed with regards to the standards practiced by the majority in the profession. The 
leading Canadian case regarding the standard of care doctors owe to their patients is Ter 
Neuzen v Korn. Here the Supreme Court concluded:  
 
It is well settled that physicians have a duty to conduct their practice in 
accordance with the conduct of a prudent and diligent doctor in the same 
circumstances. In the case of a specialist, such as a gynecologist and 
obstetrician, the doctor's behaviour must be assessed in light of the 
conduct of other ordinary specialists, who possess a reasonable level of 
knowledge, competence and skill expected of professionals in Canada, in 
that field.85  
 
Thus, a specialist like a psychiatrist, “who holds himself out as possessing a special 
degree of skill and knowledge, must exercise the degree of skill of an average specialist 
in his field.”86 To assess whether a psychiatrist breached the standard of care to a child 
or adolescent patient by prescribing SSRIs, one needs to assess the average practice of 
psychiatrists in similar circumstances. Psychiatrists, particularly child psychiatrists, will 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
83 Ibid. 
84 Bernard Dickens, “Medical Negligence” in Jocelyn Downie, Timothy Caulfield & Colleen M 
Flood eds, Canadian Health Law and Policy (Markham: LexisNexis, 2007) 102 at 103.  
85 ter Neuzen v Korn, [1995] 3 SCR 674 at para 33, 127 DLR (4th) 577. 
86 Ibid.  
 Risk v Benefits Vol 20 
!
142 
presumably be held to a higher standard than family physicians because they possess “a 
special degree of skill and knowledge” regarding mental health problems and disorders 
in children and adolescents, as well as psychopharmacology use in these populations. 
Family physicians will not be presumed to have similar knowledge since they do not 
receive the same advanced training in the area, as do psychiatrists.  
 
One way to assess whether a physician is complying with the standard of care is to 
determine if they are following guidelines set by professional organizations such as the 
CPA and the CACAP.87 If a physician does not follow such guidelines, they are 
“vulnerable to liability for negligence.” 88  The guidelines from CPA and CACAP 
concerning prescribing SSRIs to children appear to be closely followed at least by 
psychiatrists. In accordance with these guidelines, the first and most widely prescribed 
SSRI in children and adolescents is Prozac. One study found that the “SSRI usage by 
psychiatrists in the inpatient setting more closely reflects” professionally recognized 
guidelines, “than does usage in the outpatient setting.”89 However, the guidelines from 
the CPA and the CACAP both deal with medications that have not be approved for use 
in children by the country’s chief medical regulatory body, Health Canada. Surprisingly, 
it appears that guidelines from professional associations carry more weight when 
assessing the standard of care than do warnings issued by Health Canada.  
 
ii) Family Physicians 
 
The guidelines from the CPA and CACAP are of limited use since these guidelines are 
really only binding on the members of those bodies. However, most prescribers of SSRIs 
are family doctors and not members of those bodies.90 Consequently, many family 
physicians do not follow these guidelines and are thus acting in a potentially negligent 
manner when prescribing SSRIs to children and adolescents.  This is particularly 
troubling because the guidelines advise physicians not to prescribe certain SSRIs, most 
notably Paxil, due to the increased risk of suicidality in children and adolescents. 
Nonetheless, many family physicians do follow the professionally approved standard of 
care in providing weekly follow-ups and very slow increases in doses.91 Many family 
doctors simply do not know about these guidelines, thus there is a need for these doctors 
to be more aware of these guidelines.92  
 
Although many family physicians are unaware of the CPA and the CACAP guidelines 
concerning prescribing SSRIs to children, most are aware of the 2004 Health Canada 
warnings. One of the consequences of the warnings has been that many family doctors 
simply refuse to prescribe these medications to children.93 This concern was discussed 
much earlier in Health Canada’s “Scientific Advisory Panel on Selective Serotonin 
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Reuptake Inhibitors and Serotonin/Norepinephrine Reuptake Inhibitors” in 2004. In this 
panel, there were concerns that  “some non-specialist physicians who see the warning are 
over sensitive and may not prescribe, or conversely the may ignore the warnings.”94 
However, it remains to be seen whether a family physician who does not follow 
professional guidelines but follows the Health Canada warnings and does not prescribe 
SSRIs to children would be liable for negligence.  
 
The duty of care of family physicians, when confronted with depressed or anxious 
children patients, may involve a duty to refer them to a psychiatrist or another physician 
who has more training in this area. Dickens has shown that physicians “may have a duty 
of care not to treat their patients, but promptly to refer them to colleagues whose skills 
are more suited to the patients’ needs.”95 Since psychiatrists have more advanced 
knowledge than family physicians on how to treat depression and anxiety, they are better 
equipped to deal with children and adolescent patients suffering from these ailments. 
The failure of a family physician or other non-specialist physician to refer a child to a 
more suitable specialist can be considered a breach in the standard of care. 
Consequently, this would be seen as negligent since “physicians are expected to be 
aware of the limits of their own skills, and to recognize the general limits of the facilities 
in which they practice, although not necessarily on a case-by-case basis.”96 Yet, family 
physicians remain the top prescribers of SSRIs to children, which suggest they are 
treating the children themselves instead of referring them to see a psychiatrist. 
 
iii) The Locality Rule 
 
However, psychiatrists or physicians with in-depth knowledge of childhood mental 
disorders are often not available in the location in which a patient resides.  Even if a 
patient resides in an area with psychiatrists, there may not be psychiatrists who 
specialize in child psychiatry and the patient may have to wait months to get an 
appointment. While the first line of treatment in children is cognitive-behaviour therapy, 
most physicians who prescribe SSRIs for children are family practitioners who lack the 
resources to provide this therapy.97 In the past, a physician’s standard of care was 
measured against “like practitioners in the area.”98 This was known as the “locality rule.”  
However, this rule has largely fallen out of favour. One of the problems of the locality 
rule was addressed in Sunnucks v Tobique Valley Hospital, where the court noted “The 
danger is that the rural-urban distinction might create a double standard based on 
geography allowing inferior health care to be considered adequate in some areas.”99  
 
Due to the fact that Canadian Medicare and the Canada Health Act provide for equal 
access of all Canadians to receive medical care, “it appears inequitable that residents of 
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one locality may have less entitlement to a given standard of care than residents of other 
localities in the same province.”100 Thus, the inability for children to receive treatment 
from a psychiatrist or a psychologist, or to receive similar treatment as to that provided 
by a psychiatrist, is a breach of the standard of care. Whereas a psychiatrist prescribing 
SSRIs to children patients will follow the CPA and the CACAP guidelines, a family 
physician is under no obligation to follow these guidelines when prescribing SSRIs to 
children and adolescents. This creates an inequality in the treatment provided to children 
and adolescents, which could have dangerous long-term consequences for the patient. 
However, it remains to be seen whether a physician would be held liable for not referring 




Patients and Their Parents 
 
i) Age of Consent 
 
Another major issue arising from prescribing of SSRIs to children is informed consent. 
According to Rozovsky: 
 
for consent to be valid, the following criteria must be met:  
1. The patient must be legally competent to consent to treatment. 
2. The patient must possess the mental capacity to authorize care.  
3. The patient must receive a proper disclosure of information from the 
care-giver.  
4. The authorization should be specific to the procedure to be performed.  
5. The patient should have an opportunity to ask questions and to receive 
understandable answers.  
6. The authorization obtained should be free of undue influence and 
coercion.  
7. The authorization obtained should be free of misrepresentation of 
material information.101  
 
One of the requirements for informed consent is that the patient must possess the mental 
capacity to make a decision about their medical treatment. Consequently, when dealing 
with patients who are under the age of majority issues of mental capacity arise. While 
“the law presumes that all patients—including children—are legally competent to give 
an authorization for treatment,” the age of the child will certainly be a factor in assessing 
capacity.102 The age of consent is not considered to be the age of majority.103  
 
The legal ability of patients under the age of eighteen to make their own decisions about 
medical treatments varies from province to province. Many provinces have enacted 
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legislation that specifies the age of consent while other jurisdictions use the “mature 
minor” rule.104 This rule does not rely solely on a child’s age but allows the law to 
decide if children have the capacity to make treatment decisions such as whether or not 
to take SSRIs, on a case-by-case basis.105 The mature minor has been defined as “one 
with the capacity to understand the nature and consequences of medical treatment. Such 
a person has the power to consent to medical treatment and parental consent is not 
necessary.”106 Factors courts will look at to determine whether a child is a mature minor 
include: “age, maturity level, nature and extent of the minor’s dependence on parents 
and the complexity of the treatment.”107 Arguably, an adolescent will likely be deemed a 
mature minor when the treatment involves taking SSRIs, since this form of treatment is 
not as evasive or “complex” as surgery or treatment for cancer. If a child is deemed to be 
a mature minor, then physicians have the onus “to get to know their patient—just as it 
does in the adult treatment context.”108 
 
ii) Lack of Available Information for Patients and Parents 
 
If a child is deemed to be a mature minor and able to make their own decisions 
concerning whether or not to take SSRIs as a treatment for anxiety or depression, serious 
challenges still exist. Since SSRIs are a form of psychiatric treatment, a mature minor 
could face further difficulties as their mental capacity to make treatment decisions while 
suffering from a mental illness could be challenged. Further, “Youth-centred education 
and information tools” that support “knowledge sharing, shared decision-making, and 
facilitation of monitoring” of these types of medicines are largely unavailable. Informing 
children and adolescents about the risks and benefits of SSRIs is crucial because “the 
warnings and the media response invoked a fear of diagnosis and treatment among 
patients.”109  
 
The need for youth to be well informed about SSRIs is especially necessary since many 
youth use the Internet to find information about medications. This is problematic 
because of the  
 
potential lack of youths’ ability to evaluate websites, overwhelming 
information volume, uncertain credibility, incomplete information, 
inappropriate literacy levels, and the potential for those with medical 
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Without proper informational tools that allow children and adolescents to evaluate the 
risks and benefits of SSRIs, and that take into account the maturity, literacy, cognitive 
and intellectual abilities of these age groups, children and adolescents cannot to be said 
to have enough information to give informed consent. 
 
In the United States, the Food and Drug Administration’s website contains “medication 
guides” which are guides written specifically for the consumer and which detail the 
proper use of the drug and serious side effects.111 The FDA’s website also contains a 
specific section for “antidepressant use in children, adolescents and adults” which 
highlights that these medications are subject to “black box” warnings due to increased 
risks of suicidality. It also contains detailed medication guides for most major 
antidepressant medications.112  
 
Health Canada’s website contains no such detailed guides for patients and their parents. 
Although Health Canada’s website does contain drug information, it is not easily 
accessible to the public as drugs need to be searched according to their Drug 
Identification Number or Anatomical Therapeutic Chemical.113 However, since 2005 
Health Canada has operated an online Adverse Reaction Database, allowing health care 
professionals and patients “easier access to information about adverse drug reactions.”114 
Nonetheless, there is still a void in easily accessible information about SSRIs written for 
patients and their parents. 
 
iii) Informed Consent and Off-Label Prescriptions 
 
Issues surrounding informed consent are also raised due to the off-label status of SSRIs 
for use in children. For a patient or a patient’s parent to give informed consent, they must 
receive a sufficient and adequate amount of information on which to base their 
decision.115 The issue that arises with SSRI use in children is whether or not a physician 
should disclose the off-label status of these medications, i.e. that these medications have 
not been approved for use in children. However, Canadian case law is silent about “what 
a doctor is required to disclose when prescribing a drug for an off-label use.”116 Here 
again American case law is more developed. In Klein v Biscup, the plaintiff sued her 
physician for failing to tell her that the “devices used for her back surgery were not 
approved by the FDA.”117 The Court of Appeal concluded a physician does not have a 
duty to inform a patient about the off-label status of a drug or device and that “off-label 
use of a medical device is not a material risk inherently involved in a proposed therapy 
which a physician should disclose to a patient prior to the therapy.”118 In a similar case, 
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Southard v Temple University Hospital, the court “held that a physician’s failure to 
inform a patient of the FDA’s classification of a device was not a failure to obtain a 
patient’s informed consent.”119  
 
In Reibl v Hughes, the Supreme Court of Canada concluded informed consent should be 
determined by “what the average prudent person, the reasonable person in the patient’s 
particular position, would agree to or not agree to, if all material and special risks of 
going ahead with the surgery or foregoing it were made known to him.”120 Even “if a 
certain risk is a mere possibility which ordinarily need not be disclosed, yet if its 
occurrence carries serious consequences, as for example, paralysis or even death, it 
should be regarded as a material risk requiring disclosure.”121  
 
While informed consent does not involve the disclosure of every risk, it does require a 
physician to disclose the risks that would most likely affect a patient’s decision to 
undergo that treatment.122 In Ciarlariello v Schacter, the Supreme Court of Canada 
concluded the test for informed consent “focuses on what the patient would want to 
know,” and “the crucial question in determining the issue is whether a reasonable person 
in the patient’s position would want to know of the risk.”123 A patient and/or their 
parents would most likely want to know that a drug proposed by their physician has not 
been approved the country’s drug regulatory body. Knowing the off-label status of a 
drug, and the reasons why it is not approved, are reasonable requests that would satisfy 
the Ciarlariello test for informed consent.  
 
iv) Alternative Treatment Options 
 
Not only should a patient be informed about the risks and benefits of a particular 
treatment, but also about the risks and benefits of any alternative treatment options.124 
An alternative treatment option to SSRI use should be psychotherapy, specifically 
cognitive-behaviour therapy. Whether an alternative treatment will be considered 
reasonable depends on “the risk and benefits of the alternative intervention” as well as 
“the availability of the alternative test or treatment, and what is reasonable given the 
circumstances of the particular patient.”125 Psychotherapy might not be a reasonable 
alternative to many patients since they might not live in an area where there are 
psychologists. Even if they do, it could take many months to see a psychologist. If a 
patient is suicidal or severely depressed, waiting that long for treatment might not be the 
“best” option. Further, the only available psychologists may be private, an option many 
patients might not be able to afford. It is unreasonable to expect family doctors to give 
psychotherapy given their hectic workload.  Essentially, “the patient is entitled to know 
about the alternatives and the risks and advantages of each.”126 The patient and/or their 
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parents can only make an informed decision after they have received this information. 
However, this does not appear to be happening in Canada as “concerns about the risk of 
suicide in youth have led not only to fewer SSRI prescriptions without substitution of 
alternative medications or psychotherapies.”127  
 
 
IV. PROPOSAL FOR REFORM 
 
Despite the 2004 Health Canada warnings and the surrounding media attention, there is 
evidently still more work to be done. There is a glaring need for drug manufacturers, 
regulatory agencies and physicians to be more accountable and transparent. A good 
starting point for reform would be to hold drug manufacturers strictly liable if they 
discovered severe adverse reactions and side effects from their medications, either 
during Health Canada clinical trials or independent clinical trials, and did not report 
them to Health Canada. Strict liability would serve as a deterrent to drug manufacturers 
against not reporting these reactions and side effects and would help ensure that patients, 
parents, physicians and regulatory bodies are aware of any potential dangers associated 
with the use of a drug. 
 
Secondly, warnings issued by Health Canada should be considered when assessing a 
physician’s standard of care. Moreover, these warnings should be given more weight 
when a physician is considering appropriate treatments for a patient and physicians 
should not be able to simply disregard these warnings. Although there are valid uses for 
off-label prescribing in adults, extra caution should be exercised for children and 
adolescent patients. Off-label prescribing of drugs should still be used in children in 
emergency situations, or where there is no other medical alternative.  
 
However, if Health Canada has issued warnings against the use of a medication or class 
of medications, such as SSRIs, off-label prescribing of these medications should not 
occur. Given that there are other forms of treatment, such as cognitive behavioral 
therapy, that do not carry such inherent risks as SSRIs, the use of an unapproved class of 
drugs that have been subjected to governmental warnings should not be seen as a 
“reasonable” form of treatment.  Consequently, there needs to be an increased 
availability of cognitive-behaviour therapy for children and adolescents. Until there are 
multiple long-term studies, preferably conducted by a neutral party such as Health 
Canada, and conducted in accordance with the principles of the TCPS, demonstrating 
that the benefits of SSRIs in children outweigh the risks, SSRIs should simply not be 
prescribed to children and young adolescents.  
 
Nonetheless, SSRIs could still be prescribed to older adolescents provided they are 
prescribed prudently and cautiously. SSRIs have different effects on pre-pubescent 
children in comparison to older adolescents, especially adolescents approaching the age 
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of majority.128 Given the vulnerable nature of this population, physicians should exercise 
a higher standard of care when prescribing SSRIs to adolescents as opposed to 
prescribing SSRIs to adults. At minimum, adolescents and their parents need to be better 
informed. Specifically, patients and their parents need to be made aware of the off-label 
status of SSRIs and that no SSRIs have been approved by Health Canada for use in 
people under the age of eighteen. Physicians should also advise patients that many of the 
long-term risks of SSRIs are unknown and that there have been no Health Canada 
approved SSRI drug trials.  Disclosing the off-label status of SSRIs for use in 
adolescents should be considered a material risk to a patient. Not disclosing the off-label 
status of these medications should be seen as a deviation from the standard of care and 
physicians should be held liable for this nondisclosure.  
 
Further, physicians should be required to notify patients and parents to be extra vigilant 
in monitoring side effects, most notably for increases in suicidality. Family physicians 
need to become more aware of prescribing guidelines from national associations such as 
CPA and the CACAP.  These associations should hold continuing education sessions to 
provide family physicians with opportunities to learn about these guidelines. Provincial 
Colleges of Physicians and Surgeons could increase the awareness of these guidelines by 
adopting them themselves, as this would also make these guidelines binding on family 
physicians. However, despite these recommendations, the question remains whether 
knowing the off-label status of SSRIs and that many of the risks associated with SSRIs 






Depression and anxiety are two of the most prevalent disorders in the world. The need 
for safe and effective medications to combat these disorders is great. Therefore, it is not 
surprising that the emergence of SSRIs led some to “believe SSRIs have been to 
depression what antibiotics once were to bacterial infections – ‘miracle drugs.’”129 While 
SSRIs have successfully helped many adults combat depression and anxiety, the same 
cannot be said about children. For many children and adolescents, the use of SSRIs to 
treat depression and anxiety has paradoxically led to an increase in suicidality. Yet, 
surprisingly, almost a decade after the reports and studies showing this increase in 
suicidality, little has been done and children and adolescents are still widely prescribed 
these medications. 
 
The continued use of SSRIs in children and adolescents is even more surprising given 
there are government regulations in multiple countries and continents which warn 
against the use of SSRIs in children and adolescents. In Canada, SSRIs are still 
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prescribed to children and adolescents off-label as treatment for depression and anxiety, 
yet there have still been no long-term clinical studies which demonstrate that these drugs 
are safe for use in children and adolescents.  Consequently, it is frightening that there 
does not appear to be any real regulation of these medications for use in children and 
adolescents in Canada. It appears that all of the actors involved: the drug manufacturers, 
Health Canada, professional associations like CPA and CACAP, and physicians, are 
failing children and adolescents. Until there is more concrete and independently verified 
research that demonstrates the short-term and long-term consequences of SSRI use in 
children and adolescents, physicians should err on the side of caution and simply not 
prescribe these medications to children and young adolescents. While SSRIs can 
undoubtedly be “miracle drugs” for some older adolescents, the risk to the vast majority 
of others does not outweigh the benefits. Unfortunately, for many, the cure is worse than 
the disease.  
 
 
